Spironolactone and angiotensin receptor blockerin nondiabetic renal diseases

被引：17

作者：

Nitta, K ^{[1
]}

Uchida, K ^{[1
]}

Nihei, H ^{[1
]}

机构：

[1] Tokyo Womens Med Univ, Kidney Ctr, Dept Med, Tokyo, Japan

来源：

AMERICAN JOURNAL OF MEDICINE | 2004年 / 117卷 / 06期

关键词：

D O I：

10.1016/j.amjmed.2004.04.020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：444 / 445

页数：2

相关论文

共 4 条

[1] Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. [J].

Chrysostomou, A ;

Becker, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :925-926

[2] Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications [J].

Epstein, M .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (04) :677-688

[3] RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease [J].

Lakkis, J ;

Lu, WX ;

Weir, MR .

CURRENT HYPERTENSION REPORTS, 2003, 5 (05) :408-417

[4] Effectiveness of aldosterone blockade in patients with diabetic nephropathy [J].

Sato, A ;

Hayashi, K ;

Naruse, M ;

Saruta, T .

HYPERTENSION, 2003, 41 (01) :64-68